Evidence map›Paper›PMID 41312175›Full record

ArticleFrontiers in digital health2025

A hybrid PSO-AVOA framework for patient-reported drug prioritization with enhanced exploration and exploitation.

Manickavasagam Suruthi, Narayanan Ganesh

Abstract read
In one paragraph

Article in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Manickavasagam SuruthiSchool of Computer Science and Engineering, Vellore Institute of Technology, Chennai, India.
Narayanan GaneshSchool of Computer Science and Engineering, Vellore Institute of Technology, Chennai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patient-generated drug reviews are becoming increasingly available and serve as a rich source for computational drug prioritization. Methods: In this study, we developed a Hybrid Particle Swarm-Enhanced African Vulture Optimisation Algorithm (Hybrid PSO-EAVOA) that fosters the development of better balances between the exploration and exploitation of which the framework uses the improved opposition-based learning, Levy flights, and elite preservation approaches. In the framework, multiple evaluation criteria are accommodated, recovering value in the form of an overall single-objective optimization scheme, where effectiveness, side-effects, and consistency of reviews were compiled for clinical significance and combined by a weighted-sum fitness function. To validate the experiment using a large-scale dataset of drug reviews obtained from the Drugs Side Effects and Medical Condition dataset sourced from Drugs.com in Kaggle. Results: Hybrid PSO-EAVOA performed a benchmark comparison against five state-of-the-art metaheuristic algorithms (PSO, EAVOA, WHO, ALO, and HOA) using varying iterations as runs. In each comparison, Hybrid PSO-EAVOA achieved superior or better convergence speed, robustness, and quality of solutions. Discussion: The specific method of weighted-sum aggregation was used in this study, the framework offered could be easily compatible with other forms of aggregation. Hybrid PSO-EAVOA demonstrates strong potential for broader application in fields such as pharmacovigilance, clinical decision support, and drug re-purposing. The dataset is publicly available on Kaggle Drugs Side Effects and Medical Condition and all source code for parameter settings and preprocessing scripts is publicly available at the GitHub repository https://github.com/suruthi-m/Hybrid_PSO_EAVOA.

Indexed as

clinical decision support systems (CDSS)drug prioritizationenhanced African vulture optimization algorithm (EAVOA)hybrid optimizationparticle swarm optimization (PSO)precision medicine

Identifiers

PMID41312175
PMCPMC12647109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.